Latest Steatohepatitis Stories
SOUTH SAN FRANCISCO, June 30, 2014 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today
Company Presents Positive Preclinical Efficacy Results at ICE/ENDO 2014 Meeting RALEIGH, N.C., June 23, 2014 /PRNewswire/ --
RALEIGH, N.C., June 18, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing
DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease
ReportsnReports.com offers "OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" 2014 market research report in
Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals
In-demand research report “OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017” elaborated by GlobalData has been recently published by Market
New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis.
MarketResearch.com announces the addition of a new market research report in Pharmaceuticals to their product offering: OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis
- A bereavement by loss of parents or children; the state of being orbate; orbation.